Climate Compass on MSN

CRISPR and the future: Can we edit out genetic diseases?

We're living in a moment where science fiction is becoming medical reality. Imagine a world where doctors can simply rewrite ...
GEN

Why CRISPR R&D Needs to Think About Data Workflows

Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
Seeking Alpha

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...
KTLA

CRISPR screening reveals H2AZ1 as a key driver of mesenchymal stem cell aging

CRISPR-based screening identifies H2AZ1 as a driver of cellular senescence. (A) Schematic of CRISPR-based loss-of-function (LOF) screening for histone variant-associated genes (HVRGs) to identify ...
Nasdaq

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with ...
The Scientist

CRISPR-GPT Turns Novice Scientists into Gene Editing Experts

CRISPR technology has revolutionized biology, largely because of its simplicity compared to previous gene editing techniques. However, it still takes weeks to learn, design, perform, and analyze ...
Benzinga.com

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
Nasdaq

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
Nature

Dual-Amplification CRISPR Biosensor for Ultrasensitive miRNA Detection: A Powerful Tool for Cancer and Immune Monitoring

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
WDTN

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase ...

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the first investigational candidate to ...
Precision Medicine Online

Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...